BeiGene (FRA:49BA) ROCE % : -36.86% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BeiGene's annualized ROCE % for the quarter that ended in Dec. 2023 was -36.86%.

BeiGene ROCE % Historical Data

The historical data trend for BeiGene's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene ROCE % Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-58.92

-55.71

-25.83

-31.36

-26.69

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-35.38	-30.73	-28.07	-12.61	-36.86

BeiGene ROCE % Calculation

BeiGene's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1107.494	/	( ( (6022.05 - 1386.29)	+	(5323.437 - 1659.874) )	/ 2 )
	=	-1107.494	/	( (4635.76	+	3663.563)	/ 2 )
	=	-1107.494	/	4149.6615
	=	-26.69 %

BeiGene's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1407.76	/	( ( (5176.812 - 1202.449)	+	(5323.437 - 1659.874) )	/ 2 )
	=	-1407.76	/	( ( 3974.363	+	3663.563 )	/ 2 )
	=	-1407.76	/	3818.963
	=	-36.86 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BeiGene (FRA:49BA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BeiGene ROCE % Related Terms

Thank you for viewing the detailed overview of BeiGene's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines